Nitric oxide donors.

Nitric oxide (NO) donors are pharmacologically active substances that release NO in vivo or in vitro. NO has a variety of functions such as the release of prostanoids, inhibition of platelet aggregation, effect on angiogenesis, and production of oxygen free radicals. This report discusses the chemical and pharmacological characteristics of NO donors, their effect on platelet function and cyclooxygenase, their cardiac action including myocardial infarction, and release of superoxide anions. This review stresses NO tolerance and the effect of NO donors on angiogenesis in myocardial infarction and in solid tumors.

[1]  R. Grubbs,et al.  The pharmacology of a new nitric oxide donor: B-NOD. , 2000, Biochemical and biophysical research communications.

[2]  R. Bing,et al.  The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. , 2000, Life sciences.

[3]  J. Downey,et al.  Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. , 2000, Journal of molecular and cellular cardiology.

[4]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[5]  H. Fung,et al.  Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. , 2000, The Journal of pharmacology and experimental therapeutics.

[6]  Toshio Hayashi,et al.  Endothelium-dependent relaxation of rabbit atherosclerotic aorta was not restored by control of hyperlipidemia: the possible role of peroxynitrite (ONOO(-)). , 1999, Atherosclerosis.

[7]  Carlos Cordon-Cardo,et al.  At the Crossroads of Inflammation and Tumorigenesis , 1999, The Journal of experimental medicine.

[8]  S. Baldassarre,et al.  Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism. , 1999, Journal of cardiovascular pharmacology.

[9]  P. Ping,et al.  The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Harrison,et al.  Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. , 1999, Circulation.

[11]  R. Bing,et al.  Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin. , 1999, Biochemical and biophysical research communications.

[12]  R. Bing,et al.  Dexamethasone on Inducible Nitric Oxide Synthase and Nitrite/Nitrate Production in Myocardial Infarction , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  J. Marescaux,et al.  Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. , 1998, British Journal of Cancer.

[14]  R. Blantz,et al.  The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats. , 1998, European journal of pharmacology.

[15]  N. Fink,et al.  Dietary supplement with vitamin C prevents nitrate tolerance. , 1998, The Journal of clinical investigation.

[16]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[17]  E. Masini,et al.  Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. , 1998, Journal of the National Cancer Institute.

[18]  Y. Sugishita,et al.  Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. , 1998, Circulation.

[19]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[20]  T. Lüscher,et al.  Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.

[21]  Y. Sugishita,et al.  [Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance]. , 1997, Journal of cardiology.

[22]  F. Sellke,et al.  Angiogenesis and the Heart: Therapeutic Implications , 1997, Journal of the Royal Society of Medicine.

[23]  J. Beckman,et al.  Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. , 1997, Critical care medicine.

[24]  S. Moncada.  Nitric Oxide in the Vasculature: Physiology and Pathophysiology , 1997, Annals of the New York Academy of Sciences.

[25]  H. Schmidt,et al.  Just say NO to cancer? , 1997, Journal of the National Cancer Institute.

[26]  J. Wallace.  Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. , 1997, Gastroenterology.

[27]  D. Podolsky,et al.  Learning from the mistakes of Malthus: GI and manpower planning. , 1997, Gastroenterology.

[28]  P. Bellavite,et al.  The Antiplatelet Effects of a New Nitroderivative of Acetylsalicylic Acid - An In Vitro Study of Inhibition on the Early Phase of Platelet Activation and on TXA2 Production , 1996, Thrombosis and Haemostasis.

[29]  S. Rajagopalan,et al.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.

[30]  H. Granger,et al.  Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. , 1996, The American journal of physiology.

[31]  D. Warltier,et al.  Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside and nitroglycerin. , 1996, Pharmacology.

[32]  M. Currie,et al.  Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. , 1996, The Journal of clinical investigation.

[33]  B. Winkelmann,et al.  Clinical Pharmacokinetics of Molsidomine , 1996, Clinical pharmacokinetics.

[34]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[35]  L. Fontana,et al.  In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[36]  R. Bing,et al.  Effect of inhibitors of inducible form of nitric oxide synthase in infarcted heart muscle. , 1996, Proceedings of the Association of American Physicians.

[37]  F. Crivellente,et al.  Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats. , 1996, Life sciences.

[38]  J. Johnson,et al.  Parvalbumin relaxes frog skeletal muscle when sarcoplasmic reticulum Ca(2+)-ATPase is inhibited. , 1996, The American journal of physiology.

[39]  M. Hori,et al.  Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. , 1996, Circulation.

[40]  J. Wallace,et al.  Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. , 1995, The Journal of clinical investigation.

[41]  M. Curtis,et al.  Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. , 1995, Circulation research.

[42]  J. Brien,et al.  Time-dependent increase in nitric oxide formation concurrent with vasodilation induced by sodium nitroprusside, 3-morpholinosydnonimine, and S-nitroso-N-acetylpenicillamine but not by glyceryl trinitrate. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[43]  L. Barbeito,et al.  Peroxynitrite‐Induced Cytotoxicity in PC12 Cells: Evidence for an Apoptotic Mechanism Differentially Modulated by Neurotrophic Factors , 1995, Journal of neurochemistry.

[44]  J. Roberts,et al.  Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. , 1995, Circulation research.

[45]  D. Lamarque,et al.  Role of oxygen-derived metabolites in the rat gastric mucosal injury induced by nitric oxide donors. , 1995, European journal of pharmacology.

[46]  L. Keefer,et al.  Nitric Oxide (NO) Donor Molecules: Effect of NO Release Rate on Vascular Smooth Muscle Cell Proliferation In Vitro , 1995, Journal of cardiovascular pharmacology.

[47]  R. Bing,et al.  Inducible nitric oxide synthase activity in myocardium after myocardial infarction in rabbit. , 1994, Biochemical and biophysical research communications.

[48]  S. Moncada,et al.  Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Moncada,et al.  Comparative pharmacology of analogues of S‐nitroso‐N‐acetyl‐dl‐penicillamine on human platelets , 1994, British journal of pharmacology.

[50]  B. Freeman.  Free radical chemistry of nitric oxide. Looking at the dark side. , 1994, Chest.

[51]  A. Franchi,et al.  Role of nitric oxide in eicosanoid synthesis and uterine motility in estrogen-treated rat uteri. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Harrison,et al.  The Nitrovasodilators New Ideas About Old Drugs , 1993, Circulation.

[53]  J. Balligand,et al.  Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. , 1993, The Journal of clinical investigation.

[54]  C. Maragos,et al.  Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. , 1993, Cancer research.

[55]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[56]  J S Beckman,et al.  Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. , 1992, Archives of biochemistry and biophysics.

[57]  J S Beckman,et al.  Peroxynitrite formation from macrophage-derived nitric oxide. , 1992, Archives of biochemistry and biophysics.

[58]  J. Stamler,et al.  The relaxant properties in guinea pig airways of S-nitrosothiols. , 1992, The Journal of pharmacology and experimental therapeutics.

[59]  R. Hoover,et al.  Metabolism of nitroglycerin by smooth muscle cells. Involvement of glutathione and glutathione S-transferase. , 1992, Biochemical pharmacology.

[60]  D. Harrison,et al.  Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. , 1991, Biochemical pharmacology.

[61]  Y. Aniya,et al.  Nitroglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathione S‐transferase activity , 1991, British journal of pharmacology.

[62]  H. Fung,et al.  Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. , 1990, The Journal of pharmacology and experimental therapeutics.

[63]  D. Cathignol,et al.  Inhibition of Coronary Artery Thrombosis by SIN‐1, a Donor of Nitric Oxide , 1990, Journal of cardiovascular pharmacology.

[64]  D. Waters,et al.  Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. , 1990, The American journal of cardiology.

[65]  H. Fung,et al.  Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[66]  F. Murad,et al.  Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. , 1988, The Journal of pharmacology and experimental therapeutics.

[67]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[68]  F. Murad,et al.  Desensitization to nitroglycerin in vascular smooth muscle from rat and human. , 1986, Biochemical pharmacology.

[69]  D. Morel,et al.  Monocytes and Neutrophils Oxidize Low Density Lipoprotein Making It Cytotoxic , 1985, Journal of leukocyte biology.

[70]  C. A. Gruetter,et al.  Dissociation of cysteine and glutathione levels from nitroglycerin-induced relaxation. , 1985, European journal of pharmacology.

[71]  W. Klaus,et al.  The Effects of Molsidomine and Its Metabolite SIN‐1 on Coronary Vessel Tone, Platelet Aggregation, and Eicosanoid Formation In Vitro—Inhibition of 12‐HPETE Biosynthesis , 1984, Journal of cardiovascular pharmacology.

[72]  F. Murad,et al.  Agonist‐Induced Endothelium‐Dependent Relaxation in Rat Thoracic Aorta May Be Mediated through cGMP , 1983, Circulation research.

[73]  L. Ignarro,et al.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. , 1981, The Journal of pharmacology and experimental therapeutics.

[74]  K. Schrör,et al.  Stimulation of coronary vascular prostacyclin and inhibition of human platelet thromboxane A2 after low-dose nitroglycerin. , 1981, Thrombosis research.

[75]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[76]  R. Beitner,et al.  The effect of cyclic GMP on phosphofructokinase from rat tissues. , 1977, Biochimica et biophysica acta.

[77]  P. Needleman,et al.  Mechanism of tolerance development to organic nitrates. , 1973, The Journal of pharmacology and experimental therapeutics.

[78]  R. Bing,et al.  The effects of nitroglycerin on myocardial blood flow in man, measured by coincidence counting and bolus injections of 84-rubidium. , 1969, The American journal of cardiology.

[79]  R. Bing,et al.  A new method of measuring coronary blood flow in man. , 1968, JAMA.

[80]  D. Pietraforte,et al.  Role of ascorbate and protein thiols in the release of nitric oxide from S-nitroso-albumin and S-nitroso-glutathione in human plasma. , 1997, Free radical biology & medicine.

[81]  E. Chinje,et al.  Role of nitric oxide in growth of solid tumours: a balancing act. , 1997, Essays in biochemistry.

[82]  H. Granger,et al.  Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. , 1996, The American journal of physiology.

[83]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.

[84]  D. Harrison,et al.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. , 1995, The Journal of clinical investigation.

[85]  L. Keefer,et al.  Nitric oxide donors: a continuing opportunity in drug design. , 1995, Advances in pharmacology.

[86]  K. Axelsson,et al.  Lactate accumulation in isolated hypoxic rat ventricular myocardium: effect of different modulators of the cyclic GMP system. , 1993, Pharmacology & toxicology.

[87]  M. Feelisch.  The Biochemical Pathways of Nitric Oxide Formation from Nitrovasodilators: Appropriate Choice of Exogenous NO Donors and Aspects of Preparation and Handling of Aqueous NO Solutions , 1991 .

[88]  J. Hansen.  Treatment with Verapamil During and After an Acute Myocardial Infarction: A Review Based on the Danish Verapamil Infarction Trials I and II , 1991, Journal of cardiovascular pharmacology.

[89]  D. Stewart,et al.  Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. , 1989, Circulation.

[90]  M. Feelisch,et al.  On the Mechanism of NO Release from Sydnonimines , 1989, Journal of cardiovascular pharmacology.

[91]  B. Whittle.  Temporal Relationship Between Cyclooxygenase Inhibition, as Measured by Prostacyclin Biosynthesis, and the Gastrointestinal Damage Induced by Indomethacin in the Rat , 1981 .